UNSPSC 51385801: Ampiroxicam

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C20H21N3O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0PV32JZB1J, chemically known as carbonic acid, ethyl 1-((2-methyl-3-((2-pyridinylamino)carbonyl)-2h-1,2-benzothiazin-4-yl)oxy)ethyl ester, s,s-dioxide but generally known as ampiroxicam, which bears US NIH Compound Identifier 2176. European Medicines Agency schedules Ampiroxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05488MIG.

UNSPSC 51385801 Ampiroxicam is a Commodity code for a specific nonsteroidal anti-inflammatory drug; however, state and local procurement activity tagged under this code does not reflect purchases of ampiroxicam itself. The most recent opportunities solicited under the code involve broader pharmaceutical and medical supply procurement — notably naloxone and drug deactivation systems for community health programs, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products distributed through cooperative purchasing alliances. State and local buyers using this code span county health departments, state health and human services agencies, and multistate cooperative purchasing organizations that serve state and local government facilities.

Activity is centered in Florida and the upper Midwest. Seminole County, Florida issued an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with a July 26, 2023 response deadline and quarterly delivery to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 seeking vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP with a March 26, 2026 deadline for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with awarded vendors to become effective July 1, 2026 and required use of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC).